Molecular pathogenesis of retinal and choroidal vascular diseases

Progress in Retinal and Eye Research

Volumn 49, Issue , 2015, Pages 67-81

  Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Angiopoietins; Diabetic retinopathy; Hypoxia inducible factor 1; Platelet derived growth factor; TIE2; Vascular endothelial growth factor; Vascular endothelial protein tyrosine phosphatase

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; INTEGRIN; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE PHOSPHATASE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; SIGNAL PEPTIDE; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; BRUCH MEMBRANE; CHOROID DISEASE; CHOROIDAL VASCULAR DISEASES; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; HUMAN; MACULAR EDEMA; MEDICAL HISTORY; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; RETINA BLOOD VESSEL; RETINA DISEASE; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; RETINAL NONPERFUSION; RETINAL VASCULAR DISEASE; RETINAL VASCULAR LEAKAGE; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; UPREGULATION; VASCULAR DISEASE; ANIMAL; CHOROID DISEASES; DISEASE MODEL; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; RETINAL DISEASES;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; CHOROID DISEASES; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84960482943     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2015.06.002     Document Type: Review

References (121)

1. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch. Ophthalmol. 2001, 119(10):1417-1436.
2. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E.H. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 1995, 92(23):10457-10461.
3. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995, 1(10):1024-1028.
4. Auricchio A., Behling K.C., Maguire A.M., O'Conner E.M., Bennett J., Wilson J.M., Tolentino M.J. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol. Ther. 2002, 6(4):490-494.
5. Avery R.L., Castellarin A.A., Steinle N.C., Dhoot D.S., Pieramici D.J., See R., Couvillion S., Nasir M.A., Rabena M.D., Le K., Maia M., Visich J.E. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 2014, 98(12):1543-1546.
6. Bainbridge J., Mistry A., Alwis M.D., Paleolog E., Baker A., Thrasher A.J., Ali R.R. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 2002, 9(5):320-326.
7. Balaggan K.S., Binley K., Esapa M., MacLaren R.E., Iqball S., Duran Y., Pearson R.A., Kan O., Barker S.E., Smith A.J., Bainbridge J.W.B., Naylor S., Ali R.R. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther. 2006, 13(15):1153-1165.
8. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87(8):3336-3343.
9. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004, 15(4):215-228.
10. Boyer D.S. Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD). Results of a phase 1 study. Invest. Ophthalmol. Vis. Sci. 2009, 50(5). the Ophthotech Anti-PDGF in AMD Study Group, 2472.
11. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Eng. J. Med. 2006, 355(14):1432-1444. the Anchor Study Group.
12. Brown D.M., Campochiaro P.A., Singh R.P., Gray S., Rundle A.C., Li Z., Rubio R.G., Murahashi W.Y. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study. Ophthalmology 2010, 117(6):1124-1133. the CRUISE Study Group.
13. Brown D.M., Campochiaro P.A., Bhisitkul R.B., Ho A.C., Gray S., Saroj N., Adamis A.P., Rubio R.G., Murahashi W.Y. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011, 118(8):1594-1602.
14. Campochiaro P.A. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. 2004, 45(3):922-931. the C99-PKC412-003 Study Group.
15. Campochiaro P.A. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest. Ophthalmol. Vis. Sci. 2006, 47(2):462-474.
16. Campochiaro P.A., Hackett S.F. Corneal endothelial cell matrix promotes expression of differentiated features of retinal pigmented epithelial cells: implication of laminin and basic fibroblast growth factor as active components. Exp. Eye Res. 1993, 57(5):537-539.
17. Campochiaro P.A., Nguyen Q.D., Shah S.M., Klein M.L., Holz E., Frank R.N., Saperstein D.A., Gupta A., Stout J.T., Macko J., DiBartolomeo R., Wei L.L. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 2006, 17(2):167-176.
18. Campochiaro P.A., Hafiz G., Shah S.M., Nguyen Q.D., Ying H., Do D.V., Quinlan E., Zimmer-Galler I., Haller J.A., Solomon S., Sung J.U., Hadi Y., Janjua K.A., Choy D.F., Arron J.R. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Molec. Ther. 2008, 16(4):791-799.
19. Campochiaro P.A., Heier J.S., Feiner L., Gray S., Saroj N., Rundle A.C., Murahashi W.Y., Rubio R.G. Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 2010, 117(6):1102-1112. the BRAVO Study Group.
20. Campochiaro P.A., Brown D.M., Awh C.C., Lee Y., Gray S., Saroj N., Murahashi W.Y., Rubio R.G. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011, 118(10):2041-2049.
21. Campochiaro P.A., Brown D.M., Pearson A., Ciulla T., Boyer D., Holz F.G., Tolentino M., Gupta A., Duarte L., Madreperla S., Gonder J., Kapik B., Billman K., Kane F.E. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011, 118(4):626-635. the FAME Study Group.
22. Campochiaro P.A., Brown D.M., Pearson A., Chen S., Boyer D., Ruiz-Moreno J., Garretson B., Gupta A., Seenu M., Hariprasad S.M., Bailey C., Reichel E., Soubrane G., Kapik B., Billman K., Kane F.E., Green K. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012, 119(10):2125-2132. the FAME Study Group.
23. Campochiaro P.A., Bhistikul R.B., Shapiro H., Rubio R.G. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013, 120(4):795-802.
24. Campochiaro P.A., Wykoff C.C., Shapiro H., Rubio R.G., Ehrlich J.S. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients iwth diabetic macular edema. Ophthalmology 2014, 121(9):1783-1789.
25. Campochiaro P.A., Sophie R., Tolentino M., Miller D.M., Browning D., Boyer D.S., Heier J.S., Gambino L., Withers B., Brigell M., Peters K. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 2015, 122(3):545-554.
26. Channa R., Sophie R., Bagheri S., Shah S.M., Wang J., Adeyemo O., Sophie A., Wenick A., Ying H.S., Campochiaro P.A. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am. J. Ophthalmol. 2015, 159(1):9-19.
27. Davis A.A., Berstein P.S., Bok D., Turner J., Nachtigal M., Hunt R.C. A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture. Invest. Ophthalmol. Vis. Sci. 1995, 36(5):955-964.
28. Davis S., Aldrich T.H., Jones P., Acheson A., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87(7):1161-1169.
29. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H.-J., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285(5425):245-248.
30. Dobi E.T., Puliafito C.A., Destro M. A new model of choroidal neovascularization in the rat. Arch. Ophthalmol. 1989, 107(2):264-269.
31. Dong A., Seidel C., Snell D., Ekawardhani S., Ahlskog J.K., Baumann M., Shen J., Iwase T., Tian J., Stevens R., Hackett S.F., Stumpp M.T., Campochiaro P.A. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2014, 17(3):553-562.
32. Elice F., Rodeghiero F., Falanga A., Rickels F. Thrombosis associated with angiogenesis inhibitors. Best. Pract. Res. Clin. Haematol. 2009, 22(1):115-128.
33. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C.D., Kopp J.B., Gerber H.P., Ferrara N., Barisoni L., Alpers C.E., Quaggin S.E. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008, 358(11):1129-1136.
34. Fachinger G., Deutsch U., Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 1999, 18(43):5943-5948.
35. Fukai N., Eklund L., Marneros A.G., Oh S.P., Keene D.R., Tamarkin L., Neiemela M., Ilves M., Li E., Pihlajaniemi T., Olsen B.R. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 2002, 21(7):1535-1544.
36. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., Martin C., Witte C., Witte M., Jackson D., Suri C., Campochiaro P.A., Wiegand S.J., Yancopoulos G.D. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Devel. Cell. 2002, 3(3):411-423.
37. Grunwald J.E., Daniel E., Huang J., Ying G., Maguire M.G., Toth C.A., Jaffe G.J., Fine S.L., Martin D.F. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2012, 121(1):150-161. the CATT Research Group.
38. Hackett S.F., Ozaki H., Strauss R.W., Wahlin K., Suri C., Maisonpierre P., Yancopoulos G., Campochiaro P.A. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J. Cell. Physiol. 2000, 184(3):275-284.
39. Hackett S.F., Wiegand S.J., Yancopoulos G., Campochiaro P. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 2002, 192(2):182-187.
40. Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G.D., Stahl N., Vitti R., Berliner A.J., Soo Y., Anderesi M., Groetzbach G., Sommerauer B., Sandbrink R., Simader C., Schmidt-Erfurth U. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012, 119(12):2537-2548. Groups, V.A.V.S.
41. Honda M., Sakamoto T., Ishibashi T., Inomata H., Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF.flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. 2000, 7(11):978-985.
42. Igarashi T., Miyake K., Kato K., Watanabe A., Ishizaki M., Ohara K., Shimada T. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 2003, 10(3):219-226.
43. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., HuLowe D.D., Shalinsky D.R., Thurston G., Yancopoulos G.D., McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004, 165(1):35-52.
44. Iwase T., Fu J., Yoshida T., Muramatusu D., Miki A., Hashida N., Lu L., Oveson B., Lime e Silva R., Seidel C., Yang M., Connelly S., Shen J., Han B., Wu M., Semenza G.L., Hanes J., Campochiaro P.A. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J. Control. Release 2013, 172(3):625-633.
45. Kachi S., Binley K., Yokoi K., Umeda N., Akiyama H., Muramatu D., Iqball S., Kan O., Naylor S., Campochiaro P.A. EIAV vector-mediated co-delivery of endostatin and angiostatin driven by the RPE-specific VMD2 promoter inhibits choroidal neovascularization. Hum. Gene Ther. 2008, 20(1):31-39.
46. Kamba T., Tam B.Y.Y., Hashizume H., Haskell A., Sennino B., Mancuso M.R., Norberg S.M., O'Brien S.M., Davis R.B., Gowen L.C., Anderson K.D., Thurston G., Joho S., Springer M.L., Kuo C.J., McDonald D.M. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 2005, 290(2):H560-H576.
47. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., Rowan A., Yan Z., Campochiaro P.A., Semenza G.L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 2003, 93(11):1074-1081.
48. Kim I., Kim H.G., So J.-N., Kim J.H., Kwak H.J., Koh G.Y. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ. Res. 2000, 86(1):24-29.
49. Kim I., Kim J.-H., Moon S.-O., Kwak H.J., Kim N.-G., Koh G.Y. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 2000, 19(39):4549-4552.
50. Klein M.L., Ferris F.L.I., Armstrong J., Hwang T.S., Chew E.Y., Bressler S.B., Chandra S.R. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008, 115(6):1026-1031. AREDS Reseach Group.
51. Krueger N.X., Streuli M., Saito H. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J. 1990, 9(10):3241-3252.
52. Kryzstolik M.G., Afshari M.A., Adamis A.P., Gaudreault J., Gragoudas E.S., Michaud N.M., Li W., Connolly E., O'Neill C.A., Miller J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 2002, 120(3):338-346.
53. Kurihara T., Westenskow P.D., Bravo S., Afuilar E., Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J. Clin. Invest 2012, 122(11):4117-4213.
54. Kwak N., Okamoto N., Wood J.M., Campochiaro P.A. VEGF is an important stimulator in a model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2000, 41(10):3158-3164.
55. Lai C.-C., Wu W.-C., Chen S.-L., Xiao X., Tsai T.-C., Huan S.-J., Chen T.-L., Tsai R.J.-F., Tsao Y.-P. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 2001, 42(10):2401-2407.
56. Lai Y.K., Shen W.Y., Brankov M., Lai C.M., Constable I.J., Rakoczy P.E. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 2002, 9(12):804-813.
57. Lai C.M., Shen W.Y., Brankov M., Lai Y.K., Barnett N.L., Lee S.Y., Yeo I.Y., Mathur R., Ho J.E., Pineda P., Barathi A., Ang C.L., Constable I.J., Rakoczy E.P. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. 2005, 12(4):659-668.
58. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Antracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor induced mobilizatio of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA 2009, 106(7):2353-2358.
59. Lima e Silva R., Shen J., Hackett S.F., Kachi S., Akiyama H., Kiuchi K., Yokoi K., Hatara C., McLauer T., Aslam S., Gong Y.Y., Xiao W.H., Khu N.H., Thut C., Campochiaro P. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J. 2007, 21(12):3219-3230.
60. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277(5323):242-245.
61. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., Backstrom G., Fredriksson S., Landergren U., Nystrom H.C., Bergstrom G., Dejana E., Ostman A., Lindahl P., Betsholtz C. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003, 17(15):1835-1840.
62. Lukason M., Dufresne E., Hillard R., Pechan P., Li Q., Kim I., Kiss S., Flaxel C., Collins M., Miller J., Hauswirth W., MacLachlan T., Wadsworth S., Scaria A. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule 2011, 19(2):260-265.
63. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322):55-60.
64. Mameros A.G., Fan J., Yokoyama Y., Gerber H.-P., Ferrara N., Crouch R.K., Olsen B.R. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 2005, 167(5):1451-1459.
65. Mori K., Ando A., Gehlbach P., Nesbitt D., Takahashi K., Goldsteen D., Penn M., Chen C.T., Melia M., Phipps S., Moffat D., Brazzell K., Liau G., Dixon K.H., Campochiaro P.A. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am. J. Pathol. 2001, 159(1):313-320.
66. Mori K., Duh E., Gehlbach P., Ando A., Takahashi K., Pearlman J., Mori K., Yang H.S., Zack D.J., Ettyreddy D., Brough D.E., Wei L.L., Campochiaro P.A. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 2001, 188(2):253-263.
67. Mori K., Gehlbach P., Ando A., McVey D., Wei L., Campochiaro P.A. Regression of ocular neovascularization by increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 2001, 43(7):2428-2434.
68. Mori K., Gehlbach P., Ando A., Dyer G., Lipinsky E., Chaudhry A.G., Hackett S.F., Campochiaro P.A. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 2002, 43(6):2001-2006.
69. Mori K., Gehlbach P., Yamamoto S., Duh E., Zack D.J., Li Q., Berns K.I., Raisler B.J., Hauswirth W.W., Campochiaro P.A. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2002, 43(6):1994-2000.
70. Mousa S.A., Lorelli W., Campochiaro P.A. Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells. J. Cell. Biochem. 1999, 74(1):135-143.
71. Nambu H., Nambu R., Oshima Y., Hackett S.F., Wiegand S.J., Yancopoulos G., Zack D.J., Campochiaro P.A. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 2004, 11(10):865-873.
72. Nambu H., Umeda N., Kachi S., Oshima Y., Nambu R., Campochiaro P.A. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J. Cell. Physiol. 2005, 204(1):227-235.
73. Nguyen Q.D., Shah S.M., Van Anden E., Sung J.U., Vitale S., Campochiaro P.A. Supplemental inspired oxygen improves diabetic macular edema; a pilot study. Invest. Ophthalmol. Vis. Sci. 2003, 45(2):617-624.
74. Nguyen Q.D., Tatlipinar S., Shah S.M., Haller J.A., Quinlan E., Sung J., Zimmer-Galler I., Do D.V., Campochiaro P.A. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 2006, 142(6):961-969.
75. Nguyen Q.D., Shah S.M., Heier J.S., Do D.V., Lim J., Boyer D., Abraham P., Campochiaro P.A. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009, 116(11):2175-2181. READ-2 Study Group.
76. Nguyen Q.D., Brown D.M., Marcus D.M., Boyer D.S., Patel S., Feiner L., Gibson A., Sy J., Rundle A.C., Hopkins J.J., Rubio R.G., Ehrlich J.S. Ranibizumab for diabetic macular edema. Results from 2 phase III randomized Trials: RISE and RIDE. Ophthalmology 2012, 119(4):789-801. the RISE and RIDE Research Group.
77. O'Reilly M.S., Holmgren S., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage H.E., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79(2):315-328.
78. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birknead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
79. Ohno-Matsui K., Hirose A., Yamamoto S., Saikia J., Okamoto N., Gehlbach P., Duh E.J., Hackett S.F., Chang M., Bok D., Zack D.J., Campochiaro P.A. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment. Am. J. Pathol. 2002, 160(2):711-719.
80. Okamoto N., Tobe T., Hackett S.F., Ozaki H., Vinores M.A., LaRochelle W., Zack D.J., Campochiaro P.A. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 1997, 151(1):281-291.
81. Oshima Y., Deering T., Oshima S., Nambu H., Reddy P.S., Kaleko M., Connelly S., Hackett S.F., Campochiaro P.A. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J. Cell. Physiol. 2004, 199(3):412-417.
82. Oshima Y., Oshima S., Nambu H., Kachi S., Hackett S.F., Melia M., Kaleko M., Connelly S., Esumi N., Zack D.J., Campochiaro P.A. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J. Cell. Physiol. 2004, 201(3):393-400.
83. Oshima Y., Takahashi K., Oshima S., Saishin Y., Saishin Y., Silva R.L., Liang X., Reddy P.S., Ganesh S., Brann R., Liau G., Kaleko M., Connelly S., Campochiaro P.A. Intraocular gutless adenoviral vectored VEGF stimulates anterior segment but not retinal neovascularization. J. Cell. Physiol. 2004, 199(3):399-411.
84. Oshima Y., Oshima S., Nambu H., Kachi S., Takahashi K., Umeda N., Shen J., Dong A., Apte R.S., Duh E., Hackett S.F., Okoye G., Ishibashi K., Handa J., Melia M., Wiegand S., Yancopoulos G., Zack D.J., Campochiaro P.A. Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. FASEB J. 2005, 19(8):963-965.
85. Ozaki H., Hayashi H., Vinores S.A., Moromizato Y., Campochiaro P.A., Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp. Eye Res. 1997, 64(4):505-517.
86. Ozaki H., Yu A., Della N., Ozaki K., Luna J.D., Yamada H., Hackett S.F., Okamoto N., Zack D.J., Semenza G.L., Campochiaro P.A. Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 1999, 40(1):182-189.
87. Ozaki H., Seo M.-S., Ozaki K., Yamada H., Yamada E., Hofmann F., Wood J., Campochiaro P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 2000, 156(2):697-707.
88. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994, 269(41):25646-25654.
89. Patz A., Eastham A., Higgenbotham D.H., Kleh T. Oxygen studies in retrolental fibroplasia: production of the microscopic changes of retrolental fibroplasia in experimental animals. Am. J. Ophthalmol. 1953, 36(11):1511-1522.
90. Pechan P., Rubin H., Lukason M., Ardinger J., DuFresne E., Hauswirth W.W., Wadsworth S.C., Scaria A. Novel anit-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009, 16(1):10-16.
91. Petitclerc C., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras M.P., Hudson B.G., Brooks P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 2000, 275(11):8051-8061.
92. Pierce E.A., Foley E.D., Smith L.E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 1996, 114(10):1219-1228.
93. Raisler B.J., Berns K.I., Grant M.B., Beliaev D., Hauswirth W.W. Adeno-associated virus type 2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc. Natl. Acad. Sci. USA 2002, 99(13):8909-8914.
94. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Eng. J. Med. 2006, 355(14):1419-1431. Marina Study Group.
95. Rota R., Riccioni T., Zaccarini M., Lamartina S., Gallo A.D., Fusco A., Kovesdi I., Balestrazzi E., Abeni D.C., Ali R.R., Capogrossi M.C. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J. Gene Med. 2004, 6(9):992-1002.
96. Ryan S.J. Subretinal neovascularization: natural history of an experimental model. Arch. Ophthalmol. 1982, 100(11):1804-1809.
97. Saint-Geniez M., Kurihara T., Sekiyama E., Maldonado A.E., D'Amore P.A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. USA 2009, 106(44):18751-18756.
98. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 2003, 195(2):241-248.
99. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376(6535):70-74.
100. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 2000, 88(4):1474-1480.
101. Seo M.-S., Okamoto N., Vinores M.A., Vinores S.A., Hackett S.F., Yamada H., Yamada E., Derevjanik N.L., LaRochelle W., Zack D.J., Campochiaro P.A. Photoreceptor-specific expression of PDGF-B results in traction retinal detachment. Am. J. Pathol. 2000, 157(3):995-1005.
102. Shen J., Xie B., Dong A., Swaim M., Hackett S.F., Campochiaro P.A. In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest. Ophthalmol. Vis. Sci. 2007, 48(9):4335-4341.
103. Shen J., Frye M., Lee B.L., Reinardy J.L., McClung J.M., Ding K., Kojima M., Xia H., Seidel C., Lime e Silva R., Dong A., Hackett S.F., Wang J., Howard B.W., Vestweber D., Kontos C.D., Peters K.G., Campochiaro P.A. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J. Clin. Invest. 2014, 124(10):4564-4576.
104. Smith L.E.H., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35(1):101-111.
105. Stone J., Itin A., Alon T., Pe'er J., Gnessin H., Chan-Ling T., Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995, 15(7 pt 1):4738-4747.
106. Takahashi K., Saishin Y., Saishin Y., Lima Silva R., Oshima Y., Oshima S., Melia M., Paszkiet B., Zerby D., Kadan M.J., Liau G., Kaleko M., Connelly S., Luo T., Campochiaro P.A. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. 2003, 17(8):896-898.
107. The Diabetic Retinopathy Clinical Research Network, Elman M.J., Aiello L.P., Beck R.W., Bressler N.M., Bressler S.B., Edwards A.R., Ferris F.L., Friedman S.M., Glassman A.R., Miller K.M., Scott I.U., Stockdale C.R., Sun J.K. Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmolgy 2010, 117(6):1064-1077.
108. Tobe T., Okamoto N., Vinores M.A., Derevjanik N.L., Vinores S.A., Zack D.J., Campochiaro P.A. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest. Ophthalmol. Vis. Sci. 1998, 39(1):180-188.
109. Tobe T., Ortega S., Luna J.D., Ozaki H., Okamoto N., Derevjanik N.L., Vinores S.A., Basilico C., Campochiaro P.A. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 1998, 153(5):1641-1646.
110. Tolentino M.J., Miller J.W., Gragoudas E.S., Chatzistefanou K., Ferrara N., Adamis A.P. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol. 1996, 114(8):964-970.
111. Ueno S., Pease M.E., Wersinger D.M.B., Masuda T., Vinores S.A., Licht T., Zack D.J., Quigley H., Keshet E., Campochiaro P.A. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J. Cell. Physiol. 2008, 217(1):13-22.
112. Umeda N., Kachi S., Akiyama H., Zahn G., Vossmeyer D., Stragies R., Campochiaro P.A. Suppression and regression of choroidal neovascularization by systemic administration of an Alpha5Beta1 integrin antagonist. Mol. Pharmacol. 2006, 69(6):1820-1828.
113. Vinores S.A., Xiao W.H., Aslam S., Shen J., Oshima Y., Nambu H., Liu H., Carmeliet P., Campochiaro P.A. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J. Cell. Physiol. 2006, 206(3):749-758.
114. Weber B.H.F., Vogt G., Pruett R.C., Stohr H., Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat. Genet. 1994, 8(4):352-356.
115. Yacyshyn O.K., Lai P.F.H., Forse K., Teichert-Kuliszewska K., Jurasz P., Stewart D.J. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis 2009, 12(1):25-33.
116. Yamada H., Yamada E., Hackett S.F., Ozaki H., Okamoto N., Campochiaro P.A. Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. J. Cell. Physiol. 1999, 179(2):149-156.
117. Yannuzzi L.A., Negrao S., Iida T., Carvalho C., Rodriguez-Coleman H., Slakter J.S., Freund K.B., Sorenson J., Orlock D., Borodoker N. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001, 21(5):416-434.
118. Yoshida T., Zhang H., Iwase T., Shen J., Semenza G., Campochiaro P.A. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 2010, 24(6):1759-1767.
119. Yu D.Y., Cringle S.J., Su E.N., Yu P.K. Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat. Invest. Ophthalmol. Vis. Sci. 2000, 41(12):3999-4006.
120. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Molec. Cell. Biol. 2009, 29(8):2011-2022.
121. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 2008, 105(50):19579-19586.